

Michael Oellerich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6824109/publications.pdf>

Version: 2024-02-01

41
papers

2,615
citations

279798

23
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

2989
citing authors

#	ARTICLE	IF	CITATIONS
1	Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 139-152.	2.0	398
2	The Pharmacokinetic-Pharmacodynamic Relationship for Total and Free Mycophenolic Acid in Pediatric Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 759-768.	6.1	225
3	Digital Droplet PCR for Rapid Quantification of Donor DNA in the Circulation of Transplant Recipients as a Potential Universal Biomarker of Graft Injury. <i>Clinical Chemistry</i> , 2013, 59, 1732-1741.	3.2	216
4	Rapid Liquid Chromatography-Tandem Mass Spectrometry Routine Method for Simultaneous Determination of Sirolimus, Everolimus, Tacrolimus, and Cyclosporin A in Whole Blood. <i>Clinical Chemistry</i> , 2002, 48, 955-958.	3.2	188
5	Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. <i>PLoS Medicine</i> , 2017, 14, e1002286.	8.4	150
6	Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. <i>American Journal of Transplantation</i> , 2019, 19, 3087-3099.	4.7	125
7	Proteome of Conidial Surface Associated Proteins of <i>Aspergillus fumigatus</i> Reflecting Potential Vaccine Candidates and Allergens. <i>Journal of Proteome Research</i> , 2006, 5, 954-962.	3.7	113
8	Using circulating cell-free DNA to monitor personalized cancer therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 205-218.	6.1	107
9	Therapeutic Drug Monitoring of Everolimus. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 143-169.	2.0	102
10	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200.	2.0	89
11	Two-Hour Cyclosporine Concentration Determination: An Appropriate Tool to Monitor Neoral Therapy?. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 40-46.	2.0	78
12	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S1-S20.	2.0	78
13	Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. <i>Nature Reviews Nephrology</i> , 2021, 17, 591-603.	9.6	72
14	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. <i>JCI Insight</i> , 2022, 7, .	5.0	62
15	Liquid Chromatography-Tandem Mass Spectrometry or Automated Immunoassays: What Are the Future Trends in Therapeutic Drug Monitoring?. <i>Clinical Chemistry</i> , 2012, 58, 821-825.	3.2	56
16	Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 560-572.	2.0	54
17	Leveraging the real value of laboratory medicine with the value proposition. <i>Clinica Chimica Acta</i> , 2016, 462, 183-186.	1.1	50
18	Use of Graft-Derived Cell-Free DNA as an Organ Integrity Biomarker to Reexamine Effective Tacrolimus Trough Concentrations After Liver Transplantation. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 136-140.	2.0	44

#	ARTICLE	IF	CITATIONS
19	Circulating Cell-Free DNAâ€™Diagnostic and Prognostic Applications in Personalized Cancer Therapy. Therapeutic Drug Monitoring, 2019, 41, 115-120.	2.0	33
20	Biomarkers. Therapeutic Drug Monitoring, 2006, 28, 35-38.	2.0	32
21	Graft-Derived Cell-Free DNA as an Early Organ Integrity Biomarker After Transplantation of a Marginal HELLP Syndrome Donor Liver. Transplantation, 2014, 98, e43-e45.	1.0	31
22	Cell-Free Plasma DNA for Disease Stratification and Prognosis in Head and Neck Cancer. Clinical Chemistry, 2018, 64, 959-970.	3.2	27
23	SYNERGISTIC EFFECTS OF SIROLIMUS WITH CYCLOSPORINE AND TACROLIMUS: ANALYSIS OF IMMUNOSUPPRESSION ON LYMPHOCYTE PROLIFERATION AND ACTIVATION IN RAT WHOLE BLOOD. Transplantation, 2004, 77, 1154-1162.	1.0	25
24	Diagnostic value of alpha-1-fetoprotein (AFP) as a biomarker for hepatocellular carcinoma recurrence after liver transplantation. Clinical Biochemistry, 2018, 52, 20-25.	1.9	24
25	Time-Dependent Apparent Increase in dd-cfDNA Percentage in Clinically Stable Patients Between One and Five Years Following Kidney Transplantation. Clinical Chemistry, 2020, 66, 1290-1299.	3.2	24
26	Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition. Clinica Chimica Acta, 2019, 495, 481-486.	1.1	23
27	Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clinical Biochemistry, 2004, 37, 424-428.	1.9	22
28	Mycophenolic Acid Interaction With Cyclosporine and Tacrolimus In Vitro and In Vivo. Therapeutic Drug Monitoring, 2005, 27, 123-131.	2.0	18
29	Donor-Derived Cell-Free DNA Testing in Solid Organ Transplantation: A Value Proposition. journal of applied laboratory medicine, The, 2020, 5, 993-1004.	1.3	18
30	Fetal calf serum heat inactivation and lipopolysaccharide contamination influence the human T lymphoblast proteome and phosphoproteome. Proteome Science, 2011, 9, 71.	1.7	17
31	Therapeutic drug monitoring â€™ Key to personalized pharmacotherapy. Clinical Biochemistry, 2017, 50, 375-379.	1.9	15
32	Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series. Transplantation Direct, 2021, 7, e778.	1.6	15
33	Thiopurines Induce Oxidative Stress in T-Lymphocytes: A Proteomic Approach. Mediators of Inflammation, 2015, 2015, 1-14.	3.0	12
34	A Universal Droplet Digital PCR Approach for Monitoring of Graft Health After Transplantation Using a Preselected SNP Set. Methods in Molecular Biology, 2018, 1768, 335-348.	0.9	12
35	Graft-derived Cell-free DNA as a Noninvasive Biomarker of Cardiac Allograft Rejection: A Cohort Study on Clinical Validity and Confounding Factors. Transplantation, 2022, 106, 615-622.	1.0	12
36	Elevated fractional donorâ€™derived cellâ€™free DNA during subclinical graft injury after liver transplantation. Liver Transplantation, 2022, 28, 1911-1919.	2.4	12

#	ARTICLE	IF	CITATIONS
37	A value proposition for natriuretic peptide measurement in the assessment of patients with suspected acute heart failure. <i>Clinica Chimica Acta</i> , 2020, 500, 98-103.	1.1	9
38	Identification of the Novel Interacting Partners of the Mammalian Target of Rapamycin Complex 1 in Human CCRF-CEM and HEK293 Cells. <i>International Journal of Molecular Sciences</i> , 2014, 15, 4823-4836.	4.1	7
39	Crosstalk between Edc4 and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in mRNA Decapping. <i>International Journal of Molecular Sciences</i> , 2014, 15, 23179-23195.	4.1	7
40	Establishment of Thiopurine S-Methyltransferase Gene Knockdown in Jurkat T-lymphocytes. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 584-592.	2.0	5
41	Implementation of medical tests in a Value-Based healthcare environment: A framework for delivering value. <i>Clinica Chimica Acta</i> , 2021, 521, 90-96.	1.1	1